What Is Diabetes?

Diabetes is a group of chronic metabolic disorders characterized by persistently elevated blood glucose levels resulting from defects in insulin secretion, insulin action, or both. Insulin, a peptide hormone produced by beta cells in the pancreatic islets of Langerhans, enables cells to absorb glucose from the bloodstream for energy and storage; when insulin is absent, insufficient, or ineffective, glucose accumulates to concentrations that damage blood vessels and organs over time. The two primary forms are Type 1 diabetes, an autoimmune condition in which the immune system destroys beta cells entirely, and Type 2 diabetes, a progressive condition in which insulin resistance in peripheral tissues is combined with declining beta cell function. A third clinical category, gestational diabetes, occurs during pregnancy and resolves after delivery but raises lifetime risk of Type 2 diabetes.

Diabetes is significant in IEEE-adjacent fields because managing the condition depends heavily on measurement, control, and embedded systems technology. The core engineering challenge is maintaining blood glucose within a safe range, roughly 70 to 180 mg/dL, despite the variability introduced by meals, physical activity, stress, and sleep. This is a closed-loop control problem, and the evolution of its engineering solutions has tracked advances in biosensors, microcontrollers, wireless communication, and machine-learning-based prediction algorithms.

Continuous Glucose Monitoring

Continuous glucose monitors (CGMs) measure interstitial fluid glucose at intervals of one to five minutes and transmit readings wirelessly to a receiver, smartphone, or insulin pump. First made commercially available in 1999, CGMs have progressively improved in accuracy, sensor longevity, and ease of insertion, and they now provide real-time trend arrows and configurable alerts that help users anticipate glucose excursions before they become dangerous. CGM data feeds predictive algorithms that estimate where glucose will be in 30 minutes, giving automated systems and users time to act. Research on the development of insulin pump and CGM technology published in PMC documents how sensor accuracy improvements have been the enabling factor for closed-loop automation.

Insulin Delivery and Pump Technology

Insulin pumps are wearable infusion devices that deliver rapid-acting insulin continuously at a programmable basal rate, supplemented by user-commanded or algorithm-triggered bolus doses at mealtimes. Early pumps required manual programming and provided no feedback from glucose measurements; the current generation of automated insulin delivery (AID) systems connects the pump to a CGM and an onboard control algorithm that adjusts basal delivery in real time. These hybrid closed-loop systems, governed by model-predictive control or proportional-integral-derivative algorithms tuned to the slow pharmacokinetics of subcutaneous insulin absorption, have demonstrated significant improvements in time-in-range compared with multiple daily injection therapy. Clinical outcomes of sensor-augmented pump systems are reviewed in PMC research on glucose sensor-augmented insulin pump therapy.

Artificial Pancreas Systems

The artificial pancreas is the term used for fully automated closed-loop glucose control systems that handle both insulin infusion and, in bihormonal variants, glucagon delivery to prevent hypoglycemia. The engineering components are a CGM sensor, a control algorithm running on an embedded processor, and one or two infusion pumps. The control algorithm must handle meal disturbances, exercise-induced sensitivity changes, and sensor noise while maintaining safety constraints that prevent both hypoglycemia and prolonged hyperglycemia. Academic and industry research groups have conducted regulatory clinical trials, and several commercial AID systems have received approval from the U.S. Food and Drug Administration and European equivalents. The CDC's overview of diabetes management contextualizes these technologies within the broader public health burden of the disease.

Applications

Diabetes technology has applications in a wide range of disciplines, including:

• Wearable biomedical sensors for real-time metabolite monitoring
• Embedded control systems for closed-loop drug delivery
• Telemedicine platforms that transmit glucose trends to clinical teams
• Machine learning models for meal detection and insulin dose optimization